Gene Therapy Product “GT0003X” for Parkinson’s Disease Designated Under Japan’s “Regenerative Medical Products with SAKIGAKE Designation System”

ONODERA GT Pharma, Inc. (hereinafter “the Company”) is pleased to announce that today, the Ministry of Health, Labour and Welfare (MHLW) has designated GT0003X, the Company’s gene therapy product under development for Parkinson’s disease, as a target product under the “Regenerative Medical Products with SAKIGAKE Designation System.”